I was reading [the FDA guidance] differently, but again I am not familiar with these regulations. Why do you think Chromadex did an NDI for Niagen and why would a new "Niagen" not require it?
CDXC needed it because when they introduced NR, it was literally a "New Dietary Ingredient:" it had not been in supplements prior to the 1994 "grandfather." This is clear in DSHEA, and even more pointedly in the Draft Guidance: "Unless the ingredient was marketed as a dietary ingredient for use in or as a dietary supplement prior to October 15, 1994, it is an NDI."
But now that NR has passed NDI and is in supplements, it's no longer a "New Dietary Ingredient:" NR is NR is NR, and anyone else can sell it as a supplement. The raw material source doesn't matter, so long as it hasn't undergone chemical modification — by which they include modification of covalent bonds, but exclude the introduction of new salts. (Imagine the uproar if every new supplier of vitamin C or salt of B6 needed a whole new NDI ...!).
I believe what is inside Basis was either manufactured using a new process that is different from ChromaDex, thus chemical bonds were created or changed, or they used ChromaDex's process to create Niagen and then alter it. The first case require NDI and the second infringing on ChromaDex's patent. ... My best guess is a Chinese manufacturer copied the ChromaDex process and replaced Chloride with fluoride or bromide which still violate the patent.
See above on the NDI. And as I pointed out yesterday, Elysium is challenging Dartmouth's NR patents (which Chromadex licenses).
If it is a new process, a patent would have been filed already.
Possibly — though the crisis of having been cut off by CDXC might, hypothetically, have led them to rush to sale prior even to completing a patent application. However, I suspect (again) that they just have a new salt, and are expecting the patent to fall. They may think they have nothing to lose, either way: without a supply of NR, they have no basis for Basis.